Holen Sie sich die Stockscreener-App
4.60
6.31%
-0.31
Handel nachbörslich:
4.61
0.01
+0.22%
Schlusskurs vom Vortag:
$4.91
Offen:
$4.99
24-Stunden-Volumen:
3.60M
Relative Volume:
0.63
Marktkapitalisierung:
$379.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-314.85M
KGV:
-1.284
EPS:
-3.5825
Netto-Cashflow:
$-283.27M
1W Leistung:
-2.13%
1M Leistung:
+90.08%
6M Leistung:
-54.27%
1J Leistung:
-44.91%
1-Tages-Spanne:
$4.505
$5.01
1-Wochen-Bereich:
$4.505
$5.55
52-Wochen-Spanne:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
4.60 | 405.43M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Herabstufung | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-04-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
Replimune Group stock (US76029N1063): insider selling and legal probe put focus on biotech story - AD HOC NEWS
Ridgeback Group Reports 6.25M Shares in Replimune (REPL) - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - PR Newswire
Replimune group CAO sells $40,101 in common stock By Investing.com - Investing.com India
Replimune group CAO sells $40,101 in common stock - Investing.com
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Replimune (REPL) accounting chief sells 7,894 shares to cover RSU taxes - Stock Titan
Tax-cover sale: Replimune (NASDAQ: REPL) CCO offloads 8,626 shares - Stock Titan
Replimune (REPL) director tax-related sale covers RSU withholding - Stock Titan
Replimune shares plunge 64% after FDA rejects melanoma treatment application, investors join fraud probe. - Pluang
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the ... - Caledonian Record
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What's going on with Replimune stock on Tuesday? - MSN
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL SEC FilingsReplimune Group 10-K, 10-Q, 8-K Forms - Stock Titan
RTW Investments, R. Wong report 7.36M shares in Replimune (NASDAQ: REPL) - Stock Titan
REPL Technical Analysis | Trend, Signals & Chart Patterns | REPLIMUNE GROUP INC (NASDAQ:REPL) - ChartMill
Replimune surges day after FDA Commissioner Makary resigns - MSN
Opinion | The FDA and My Daughter’s Death From Cancer - WSJ
Micron Rallied 90% In A Month — These 10 Small‑Cap Stocks Blew Past It - Benzinga
REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1 (NASDAQ:REPL) - Seeking Alpha
Replimune Group Stock Short Interest Rises to 50.44% - Moomoo
Suvretta (REPL) reports 4,221,836 shared holdings in Replimune (5.1%) - Stock Titan
Replimune (REPL) Stock Rises Amid FDA Commissioner Marty Makary's Departure - GuruFocus
Replimune Group stock (US76029N1063): FDA rejection of RP1 melanoma therapy draws backlash - AD HOC NEWS
REPLIMUNE GROUP SHARES ADD 3.2% AFTER NEARLY 22% GAIN IN PREVIOUS SESSION - Moomoo
TradingKey - TradingKey
Number of shareholders of Replimune Group, Inc. – LSX:A2JQN1 - TradingView
REPL Soars As Trump FDA Shake-Up Revives RP1 Hopes - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Replimune (REPL) Shares Surge on FDA Developments - GuruFocus
REPL Stock Jumps As Wall Street Journal Challenges FDA - StocksToTrade
Replimune shares surge on report Trump to dismiss FDA chief Makary - Investing.com Australia
The FDA, Replimune and Patients Like Me - WSJ
T. Rowe Price (REPL) files 13G/A showing 157,965 shares (0.2%) ownership - Stock Titan
MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA - Streetwise Reports
How many employees work at Replimune Group? - reveliolabs.com
What's Going On With Replimune Stock On Tuesday? - Sahm
FDA Commissioner Makary defends agency’s decision on Replimune’s drug, CNBC reports - hi99.com
FDA head Makary defends drug application rejections amid criticism - Seeking Alpha
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
| Sarchi Christopher | Chief Commercial Officer |
Apr 02 '26 |
Sale |
8.01 |
6,500 |
52,065 |
151,588 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):